Enhancing oncology research through data sharing and re-use: A five-year review of Vivli's global data platform.

Abstract

e13670 Background: The last decade has seen a paradigm shift in clinical research with the accessibility of trial data, facilitating secondary analyses and the development of novel predictive models. Vivli a non-profit entity established in 2018, epitomizes this movement with its global platform (vivli.org) dedicated to the facilitating access to and re-use of individual participant data from completed clinical trials for use by researchers worldwide. Methods: Commencing with approximately 2,500 trials from 15 members, Vivli has expanded over five years to encompass more than 7,000 trials involving 3.6 million participants across 50 members who contribute trial data from various sectors (industry, academic, government and non-profit foundation). Results: Oncology trials constitute 11% of the Vivli data pool of 7,000 trials, constituting 36% of Vivli’s research proposals due to the therapeutic area's high-impact potential. Researchers accessing data in the Vivli platform have produced a significant body of scientific work, with 74 oncology-focused publications emerging from their analyses. Notably, Roche's data has been a key resource, denoted by the 28% of all Vivli proposals requesting access to Roche data. Fifty-eight publications have resulted from secondary analysis of Roche oncology data. The motivation for secondary analyses in oncology have been predominantly for new research into treatment effectiveness or safety (39%). Other reasons include confirmation of existing research (15%), individual participant data (IPD) meta-analysis (14%), statistical method (10%), clinical trial design (5%), and summary-level meta-analysis (4%), training/testing (7%), other (5%). Conclusions: The Vivli platform has proven to be a key resource in recent years for the oncology community enabling the integration and publication of new insights. The sharing of IPD is in part motivated to ensure reproducibility of findings; our experience demonstrates that a minority of researchers are interested in reproducibility analysis but the majority of research is focused on new insight generation. The platform's success in facilitating the findability, accessibility and reuse of patient level data is signified by ever increasing numbers of scientific publications emerging from analyses on the Vivli platform and this underscores its role in advancing scientific discovery and development within the field of oncology.